Founded in 1997 by SmithKline Beecham (now GlaxoSmithKline) and Incyte, diaDexus, Inc. is a privately held biotechnology company focused on discovering, developing, and commercializing novel, patent-protected diagnostic products with high clinical value.

The PLAC® Test

In June 2005, the FDA cleared the PLAC test as the first blood test for determining the risk for ischemic stroke associated with atherosclerosis. In July 2003, diaDexus received FDA clearance to market the PLAC test as an aid in the prediction of coronary heart disease (CHD) risk. The PLAC test determines levels of Lp-PLA₂ (lipoprotein-associated phospholipase A₂) in the blood; individuals with elevated levels of Lp-PLA₂ have been shown to have an increased risk of ischemic stroke and coronary heart disease.

To learn more about diaDexus, visit us online.

"Welcome to the PLAC test website.

The PLAC test is an important step forward in the use of genomics to create powerful new diagnostic tools. As an organization, we are dedicated to finding ways to support medical professionals in their work saving and improving lives."